Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discovery of Clinical Candidate GLPG3970: A Potent and Selective Dual SIK2/SIK3 Inhibitor for the Treatment of Autoimmune and Inflammatory Diseases.
Peixoto C, Joncour A, Temal-Laib T, Tirera A, Dos Santos A, Jary H, Bucher D, Laenen W, Pereira Fernandes A, Lavazais S, Delachaume C, Merciris D, Saccomani C, Drennan M, López-Ramos M, Wakselman E, Dupont S, Borgonovi M, Roca Magadan C, Monjardet A, Brys R, De Vos S, Andrews M, Jimenez JM, Amantini D, Desroy N. Peixoto C, et al. Among authors: jimenez jm. J Med Chem. 2024 Apr 11;67(7):5233-5258. doi: 10.1021/acs.jmedchem.3c02246. Epub 2024 Mar 29. J Med Chem. 2024. PMID: 38552030 Free PMC article.
Discovery of GLPG3667, a Selective ATP Competitive Tyrosine Kinase 2 Inhibitor for the Treatment of Autoimmune Diseases.
Mammoliti O, Martina S, Claes P, Coti G, Blanque R, Jagerschmidt C, Shoji K, Borgonovi M, De Vos S, Marsais F, Oste L, Quinton E, López-Ramos M, Amantini D, Brys R, Jimenez JM, Galien R, van der Plas S. Mammoliti O, et al. Among authors: jimenez jm. J Med Chem. 2024 Jun 13;67(11):8545-8568. doi: 10.1021/acs.jmedchem.4c00769. Epub 2024 May 28. J Med Chem. 2024. PMID: 38805213 Free PMC article. Clinical Trial.
Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors.
Charrier JD, Miller A, Kay DP, Brenchley G, Twin HC, Collier PN, Ramaya S, Keily SB, Durrant SJ, Knegtel RM, Tanner AJ, Brown K, Curnock AP, Jimenez JM. Charrier JD, et al. Among authors: jimenez jm. J Med Chem. 2011 Apr 14;54(7):2341-50. doi: 10.1021/jm101499u. Epub 2011 Mar 10. J Med Chem. 2011. PMID: 21391610
Discovery of Selective, Orally Bioavailable Pyrazolopyridine Inhibitors of Protein Kinase Cθ (PKCθ) That Ameliorate Symptoms of Experimental Autoimmune Encephalomyelitis.
Collier PN, Twin HC, Knegtel RMA, Boyall D, Brenchley G, Davis CJ, Keily S, Mak C, Miller A, Pierard F, Settimo L, Bolton CM, Chiu P, Curnock A, Doyle E, Tanner AJ, Jimenez JM. Collier PN, et al. Among authors: jimenez jm. ACS Med Chem Lett. 2019 Jun 27;10(8):1134-1139. doi: 10.1021/acsmedchemlett.9b00134. eCollection 2019 Aug 8. ACS Med Chem Lett. 2019. PMID: 31417666 Free PMC article.
Structure-based optimization of aminopyridines as PKCθ inhibitors.
Jimenez JM, Davis C, Boyall D, Fraysse D, Knegtel R, Settimo L, Young S, Bolton C, Chiu P, Curnock A, Rasmussen R, Tanner A, Ager I. Jimenez JM, et al. Bioorg Med Chem Lett. 2012 Jul 15;22(14):4645-9. doi: 10.1016/j.bmcl.2012.05.114. Epub 2012 Jun 6. Bioorg Med Chem Lett. 2012. PMID: 22738630
221 results